Stylianos Kakolyris - Concepedia

Author

Stylianos Kakolyris

Democritus University of Thrace

Also Known As

Bing Xu, S Kakolyris, S. KAKOLYRIS, S. Kakolyris, S.A. Kakolyris, STYLIANOS KAKOLYRIS, Stylianos Kakolyris

184

Publications

5.1K

Citations

H-Index

102

Concepts

All Affiliations

Democritus University of Thrace University Hospital of Heraklion University Hospital of Alexandroupolis National and Kapodistrian University of Athens University of Crete

About

Stylianos Kakolyris is an author at Democritus University of Thrace specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	45	2.7K
2	Health Sciences	11	12	1.1K
3	Natural Sciences	1	1	12
4	Nursing	1	1	45
5	Public Health	1	1	45

Stylianos Kakolyris

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) John Souglakos, N. Androulakis, K. Syrigos, British Journal of Cancer	2006	399
Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer Nikolaos Xenidis, Michail Ignatiadis, Stella Apostolaki, Journal of Clinical Oncology	2009	240
Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial Vassilis Georgoulias, Alexandros Ardavanis, Xanthi Tsiafaki, Journal of Clinical Oncology Advanced NsclcOncologyMedicineChemotherapyVc Arms	2005	163
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) D. Mavroudis, Emmanouil Saloustros, N. Malamos, Annals of Oncology Breast OncologyOncologyDose-dense ChemotherapyBreast CancerAdjuvant Trastuzumab	2015	162
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Michael I. Koukourakis, Alexandra Giatromanolaki, P E Thorpe, PubMed ImmunologyPathologyTumor BiologyNsclc CasesAngiogenesis	2000	149
Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers Makrina Karaglani, Ioanna Balgkouranidou, Eirini Biziota, Oncogene Breast OncologyOncologyNucleic Acid BiomarkersCancer DetectionTumor Heterogeneity	2019	144
Triplet Combination With Irinotecan Plus Oxaliplatin Plus Continuous-Infusion Fluorouracil and Leucovorin as First-Line Treatment in Metastatic Colorectal Cancer: A Multicenter Phase II Trial John Souglakos, D. Mavroudis, Stylianos Kakolyris, Journal of Clinical Oncology	2002	119
Transtympanic Injections of N-acetylcysteine for the Prevention of Cisplatin-induced Ototoxicity Maria Riga, Leonidas Chelis, Stylianos Kakolyris, American Journal of Clinical Oncology	2011	108
mTOR pathway: A current, up-to-date mini-review (Review) Paul Zarogoulidis, Sofia Lampaki, J. Francis Turner, Oncology Letters Chemoprevention StrategyPathologyMtor PathwayTumor BiologyOncology	2014	107

Page 1